Alaunos Therapeutics Files 10-Q, Details R&D and G&A Expenses

TL;DR

Alaunos 10-Q out: R&D and G&A expenses detailed, MD Anderson/Texas A&M deals mentioned.

AI Summary

Alaunos Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported research and development expenses for the six months ended June 30, 2023, and general and administrative expenses for the three months ended June 30, 2024. The filing also references a CRADA Agreement Member and a license and research and development agreement with The University of Texas MD Anderson Cancer Center and The Texas A&M University System.

Why It Matters

This filing provides insight into Alaunos Therapeutics' operational expenses and ongoing research collaborations, which are crucial for understanding the company's financial health and future development pipeline.

Risk Assessment

Risk Level: medium — The filing details operational expenses and agreements, but lacks specific financial performance metrics like revenue or profit, indicating a need for further financial analysis.

Key Numbers

• 20240630 — Reporting Period End Date (The end date for the financial information presented in the 10-Q.)
• 20240814 — Filing Date (The date the 10-Q was officially filed with the SEC.)
• 2023-06-30 — Previous Period End Date (The end date for comparative financial data from the prior year.)

Key Players & Entities

• Alaunos Therapeutics, Inc. (company) — Filer of the 10-Q
• The University of Texas MD Anderson Cancer Center (company) — Party to a license and R&D agreement
• The Texas A&M University System (company) — Party to a license and R&D agreement
• ZIOPHARM ONCOLOGY INC (company) — Former company name
• EASYWEB INC (company) — Former company name
• Intrexon Corporation (company) — Mentioned in relation to a date

FAQ

Key Financial Figures

• $0.001 — hares of the registrant's common stock, $0.001 par value, was 1,601,252 shares. SPEC
• $2,500,000 — in our shareholder equity falling below $2,500,000 as required by Nasdaq Listing Rule 5550

Filing Documents

• tcrt-20240630.htm (10-Q) — 1305KB
• tcrt-ex31_1.htm (EX-31.1) — 13KB
• tcrt-ex32_1.htm (EX-32.1) — 7KB
• 0000950170-24-097142.txt ( ) — 4526KB
• tcrt-20240630.xsd (EX-101.SCH) — 887KB
• tcrt-20240630_htm.xml (XML) — 416KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 15 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 20 Item 4.

Controls and Procedures

Controls and Procedures 20 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 21 Item 1A.

Risk Factors

Risk Factors 21 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 48 Item 3. Defaults Upon Senior Securities 48 Item 4. Mine Safety Disclosures 48 Item 5. Other Information 48 Item 6. Exhibits 50 1

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Condensed Financial Statements

Item 1. Condensed Financial Statements Alaunos Therapeutics, Inc. CONDENSED BALANCE SHEETS (unaudited) (in thousands, except share and per share data) June 30, December 31, 2024 2023 ASSETS: Current assets: Cash and cash equivalents $ 2,463 $ 6,062 Receivables 4 1 Prepaid expenses and other current assets 2,211 2,198 Total current assets 4,678 8,261 Property and equipment, net — 2 Total assets $ 4,678 $ 8,263 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 365 $ 616 Accrued expenses 542 1,340 Total current liabilities 907 1,956 Total liabilities $ 907 $ 1,956 Commitments and contingencies Stockholders' equity Common stock $ 0.001 par value; 5,000,000 shares authorized, 1,601,252 shares issued and outstanding at June 30, 2024 and at December 31, 2023 2 2 Additional paid-in capital 922,346 922,072 Accumulated deficit ( 918,577 ) ( 915,767 ) Total stockholders' equity 3,771 6,307 Total liabilities and stockholders' equity $ 4,678 $ 8,263 The accompanying notes are an integral part of these condensed financial statements. 2 Alaunos Therapeutics, Inc. CONDENSED STATEMENTS OF OPERATIONS (unaudited) (in thousands, except share and per share data) For the Three Months Ended June 30, For the Six Months Ended June 30, 2024 2023 2024 2023 Revenue $ 4 $ 4 $ 6 $ 4 Operating expenses: Research and development 180 5,186 306 11,689 General and administrative 990 3,045 2,607 6,213 Gain on lease modification — ( 245 ) — ( 245 ) Total operating expenses 1,170 7,986 2,913 17,657 Loss from operations ( 1,166 ) ( 7,982 ) ( 2,907 ) ( 17,653 ) Other income (expense): Interest expense — ( 1,068 ) — ( 1,921 ) Other income, net 37 277 97 753 Other income (expense), net 37 ( 791 ) 97

View Full Filing

View this 10-Q filing on SEC EDGAR